Cassiopeia myeloma
Web26 May 2024 · 8003 Background: VTd is a standard of care (SoC) for TE NDMM. CD38 mAb DARA significantly reduced the risk of progression/death and improved CR and MRD … Web26 May 2024 · CASSIOPEIA is the first study to demonstrate clinical benefit of DARA + SoC in TE NDMM. Clinical trial information: NCT02541383. Post-consolidation (D 100 Post-ASCT) Response and MRD-negative Rates: ITT. © …
Cassiopeia myeloma
Did you know?
Web8 Apr 2024 · CASSIOPEIA was a randomized, open-label, phase III trial evaluating the inclusion of daratumumab with VTd before and after ASCT for transplant-eligible patients … Web23 Nov 2024 · Conclusion: In CASSIOPEIA, the highest and most durable rates of MRD negativity were achieved after D-VTd ind/ASCT/cons and DARA maintenance. Reduced intensity (Q8W) DARA maintenance did not significantly improve MRD negativity compared to OBS in patients treated with D-VTd.
Web21 Oct 2024 · Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells. 1 Multiple myeloma is the third most common blood... Web15 Apr 2024 · This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2024. After some key meetings of the discipline of the field of clinical hematology, the …
WebMain info Identifier: HO131 MM / IFM 2015-01 (Cassiopeia) Sponsor: IFM Working group party: Myeloma Age: 18-65 Stage: 1st Line Echelon: Limited Site Selection Web4 Sep 2015 · A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia) The safety and scientific …
Web2 Feb 2024 · People with untreated multiple myeloma would welcome a new option for first-line treatment . 3.1 . Patient experts explained that multiple myeloma is a relapsing and remitting disease and can include severe symptoms. The first remission is often the 'best' remission because people are at their fittest. With each
Web4 Jun 2024 · Daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone (D-Rd) resulted in consistently deep and durable responses compared with Rd alone for patients with transplant-ineligible newly diagnosed multiple myeloma, regardless of renal function or cytogenetic risk, according to a subgroup analysis from the phase 3 MAIA trial … slowmag chplWeb5 Nov 2024 · The protocol of the Cassiopeia trial included instructions of discontinuation and dose modification, when PNP grade ≥2 was observed. However, in a subset of … software rk100WebOverview. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer. Bone marrow is the spongy tissue at the centre of some bones that produces the body's … software risk management categoriesWeb• Most common side effects reported in CASSIOPEIA trial: The most common haematological toxicities reported were: neutropenia (all grade: 29%, ≥G3- 4: 28%), … software rkWebHigh-risk cytogenetic abnormalities and International Staging System (ISS) disease stage III confer poor outcomes in MM pts. In the phase 3 CASSIOPEIA study, at median follow … software risk management processWeb11 Jul 2024 · Shaji Kumar, MD. At ASCO 2024, Shaji Kumar, MD, talked about the impact of adding daratumumab maintenance to therapy for patients with newly diagnosed multiple … slow mag ceneoWeb19 Jun 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple … software risk control measures